ARTICLES BY DAVID ADLER
-
![business man looking through telescope-GettyImages-2215651052]( "Why Oncology Programs Can't Rely On An Inside View Alone")
9/18/2026Discover how looking outside a program can help oncology teams test assumptions, improve feasibility, and make stronger development decisions.
-
![metal chain-GettyImages-638503806]( "Medical Affairs: The Missing Link To Oncology Drug Adoption")
9/11/2026Learn how medical affairs can help oncology teams turn strong clinical evidence into real-world adoption by connecting development strategy with clinical practice.
-
![cancer treatment, Chemotherapy-GettyImages-1817198559]( "Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections")
8/27/2026Promising pediatric cancer science often stalls before patients benefit. David Adler explains how better connections could change that.
David Adler
Professor David Adler, MD, Ph.D., MBA, is a senior oncology drug development and translational medicine leader with more than 15 years of experience spanning pharmaceutical development and academic cancer research. He spent a decade in senior medical and clinical development leadership within Bayer AG’s Global Oncology Clinical Development organization, leading oncology programs from preclinical research into the clinic. He currently serves as chief scientific & medical officer of the PATHORA Institute of Pathology & Tissue Medicine. His work focuses on the strategic decisions that shape the path from scientific discovery through clinical development and help determine whether promising innovations can ultimately become medicines. He also holds academic appointments at the Hebrew University of Jerusalem, Ben-Gurion University of the Negev, and the University of Bonn.